[Influence of the plaferon on healing of burned wounds of III - IV degrees].
The purpose of the given work was studying influence of a preparation Plaferon on the process of healing burned wounds. Experiments was carried out on 30 rats Wistar (the mass of body 220-250 g), that was divided into 3 groups: 1st group (control) -burns without treatment, 2nd group - treatment only with Dermazin, 3rd group - treatment with Dermazin and Plaferon. As a result of the burn wound modeling, it is established that under the effect of the thermal interaction the rats of all experimental groups had severe burns of the skin of III degree. After 5-10 days of observation the degree of necrotic changes in the burn surface in animal experimental groups was different. They were least expressed in the rats, that obtained treatment by Plaferon and Dermazin; further in increasing order of magnitude was located the group of the rats, that obtained treatment only by Dermazin. The greatest necrotic changes were noted in control animals. With a morphological study of wound defects with the treatment of Plaferon and Dermazin for 30 days in most of rats was noted the epithelization of the wounds. The rats, that obtained the treatment of the burns only by preparation of Dermazin, on the surface of wounds had the remainders of scab in the form the fibrous- leukocyte layer, under which was located granulating cloth with the regulated motion of weakly-fuxinophilous collagenic fibers. Summing up studying of influence Plaferon on healing of severe thermal burn of the skin in rats, it should be noted, that application of Plaferon together with drawing of preparation Dermazin on burned surface right after burning traumas daily, unitary, within the next 30 days noticeably weakens development of severe necrotic processes and accelerates healing of the burn.
Vadachkoriia
E O
EO
Iashvili
B P
BP
Belikov
Iu N
IuN
Matsaberidze
G Sh
GSh
Sudzhashvili
L T
LT
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage; D002056:Burns / Q000188:drug therapy*; D003131:Combined Modality Therapy; D005260:Female; D009479:Neuropeptides / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012837:Silver Sulfadiazine / Q000008:administration & dosage; D012867:Skin / Q000187:drug effects* / Q000293:injuries; D014945:Wound Healing / Q000187:drug effects*
D000891:Anti-Infective Agents, Local; D009479:Neuropeptides; C091912:plaferon; D012837:Silver Sulfadiazine